FDA found Pharmedica made ophthalmic and nasal drugs under insanitary conditions without required sterile controls.
What happened
FDA inspected Pharmedica's Phoenix drug manufacturing facility from November 1 to November 7, 2022 and found insanitary conditions, including no ISO classified areas such as ISO 5 for sterile drug production and a facility in disrepair. FDA also cited CGMP violations: no adequate aseptic or sterility controls for an OTC ophthalmic product, no process validation, inadequate release and component testing, and an inadequate quality unit. The company later ceased drug manufacturing and recalled Purely Soothing 15% MSM Drops worldwide because they were not sterile.
What FDA found
FDA found sterile-intended ophthalmic drug products made in a facility that lacked ISO classified areas and was in disrepair, creating a risk of contamination.
section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A)The firm lacked adequate written procedures and validation to prevent microbiological contamination and did not have adequate separate or defined aseptic processing areas.
21 CFR 211.113(b) & 211.42(c)(10)The firm did not qualify equipment or validate manufacturing processes, including process performance qualification and ongoing process monitoring.
21 CFR 211.100(a)The firm did not perform adequate release testing for each batch, including sterility testing for ophthalmic products and testing for objectionable microorganisms in nasal spray.
21 CFR 211.165(a) and 21 CFR 211.165(b)The firm did not adequately test components and did not establish the reliability of supplier test results or obtain and review all supplier certificates of analysis.
21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)The quality control unit failed to ensure adequate procedures, a stability program, complete batch records, and adequate deviation investigations.
21 CFR 211.22, 211.166(a), 211.188, 211.192
What FDA wants
FDA tells Pharmedica to correct the violations promptly and respond in writing within 15 working days with the actions taken and plans to prevent recurrence. If the firm resumes drug manufacturing, it must notify FDA before resuming and provide a CAPA summary; FDA also recommends a qualified consultant and a six-system CGMP audit.
Who should pay attention
- brands that contract with Pharmedica for ophthalmic or nasal drug products
- companies buying or distributing Purely Soothing products
- drug manufacturers outsourcing sterile ophthalmic production
This is a summary. Read the original letter on fda.gov.